Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04895605 · ClinicalTrials.gov registry record

An Evaluation of Low Level Laser Light Therapy for Autistic Disorder 2

A clinical trial of Autistic Disorder, sponsored by Erchonia Corporation.

Completed
Registry status
40
Enrollment target
1
Study location

NCT04895605 is a study of Autistic Disorder that has completed, run by Erchonia Corporation. The registered enrollment target is 40 participants, below the 112-participant average among 27 other Autistic Disorder trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04895605, a study of Autistic Disorder, has completed, sponsored by Erchonia Corporation.

COMPLETED
Registry status
40 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether the Erchonia HLS Laser is effective in the treatment of irritability associated with autistic disorder in children and adolescents aged five (5) to twelve (12) years.

Conditions Studied

Interventions

  • DEVICE Placebo Laser
  • DEVICE Erchonia HLS Laser

Study Locations (1)

Massachusetts

  • Spaulding Rehabilitation Hospital - Boston

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2020-11-11
Est. Completion 2022-03-17

Sponsor

Erchonia Corporation

34 total trials

What the Registry Record Tells You About NCT04895605

The ClinicalTrials.gov registry entry for NCT04895605 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 112-participant average among 27 other Autistic Disorder trials with a reported enrollment target (64% lower). The listed sponsor is Erchonia Corporation, which has 34 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Autistic Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo Laser is the first listed.

NCT04895605 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04895605 about?

NCT04895605 is a clinical study titled "An Evaluation of Low Level Laser Light Therapy for Autistic Disorder 2". The purpose of this study is to determine whether the Erchonia HLS Laser is effective in the treatment of irritability associated with autistic disorder in children and adolescents aged five (5) to twelve (12) years.

What is the current status of trial NCT04895605?

This trial is currently completed. The enrollment target is 40 participants. The study started on 2020-11-11. Estimated completion is 2022-03-17.

What conditions does trial NCT04895605 study?

This clinical trial studies the following conditions: Autistic Disorder.

What interventions are being tested in trial NCT04895605?

The interventions under investigation include: Placebo Laser (DEVICE), Erchonia HLS Laser (DEVICE).

Who is sponsoring clinical trial NCT04895605?

This trial is sponsored by Erchonia Corporation, which has 34 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04895605 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autistic Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.